ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint744,947 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryZugPharvaris GmbH
Pharvaris GmbH Logo
Verified· 2 sources

Pharvaris GmbH

Summary

About the company

Pharvaris GmbH is a late‑stage biopharmaceutical company developing novel oral bradykinin B2‑receptor antagonists. The company focuses on bradykinin‑mediated diseases, including hereditary angioedema (HAE) and acquired angioedema due to C1‑inhibitor deficiency, and is developing deucrictibant in immediate‑release and extended‑release formulations for on‑demand and prophylactic treatment.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
✓ Offered6
Development of oral therapies for bradykinin-mediated angioedema
Development of investigational oral therapies based on bradykinin B2 receptor antagonists for bradykinin-mediated angioedema, in particular hereditary angioedema and AAE-C1INH.
Clinical development of Deucrictibant
Investigational orally administered bradykinin B2 receptor antagonist in clinical development for prevention and acute treatment of HAE and AE-BK attacks.
Prevention of HAE attacks
Once-daily oral extended-release tablet with Deucrictibant for prevention of HAE attacks; therapeutic exposure over 24 hours and Phase 3 development.
On-demand treatment of HAE attacks
Oral immediate-release capsule with Deucrictibant for the rapid treatment of HAE attacks; therapeutic exposure within 15–20 minutes and Phase 3 development.
Development of therapies for AAE-C1INH
Development of treatment approaches for acquired angioedema due to C1-INH deficiency as a bradykinin-mediated disease within the clinical pipeline.
Scientific publications
Publications of scientific findings and research data, available via the publication overview.
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
Comparisons

Pharvaris GmbH in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Pharvaris GmbH by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Pharvaris GmbH to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Grafenauweg 8
6300 Zug

At a glance

Legal form
Limited Liability Company
UID
CHE-462.641.977
Founded
2020 · 6 years
Last commercial register change
January 17, 2024
Employees
11 to 20

Knowledge

No knowledge articles yet

Once Pharvaris GmbH has claimed this profile, we'll publish editorial articles and case studies here together.

Get started

Similar companies

KP
KalVista Pharmaceuticals Switzerland GmbH
Zug
AP
Aphaia Pharma AG
Zug
BM
Blueprint Medicines (Switzerland) GmbH
Zug
EB
Enable Biotech AG
Zug
CA
Cellis AG
Zug
C(
Cytokinetics (Switzerland) GmbH
Zug
NT
Nektar Therapeutics Europe GmbH
Zug
IB
Iovance Biotherapeutics GmbH
Zug